Krystal Biotech (KRYS) reported first-quarter 2025 earnings per share (EPS) of $1.20, which missed the Zacks Consensus Estimate of$1.38.  Nonetheless, the reported EPS was up from 3 cents posted in the year-ago quarter. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)Revenues of $88.1 million surged 95$95 million. Revenues came in solely from the sales of Vyjuvek.Shares of the company are trading down in response to the di ...